NCT03927144: A reported trial by Amgen
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03927144 |
|---|---|
| Title | A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Active-controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (AMG334 qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 15, 2019 |
| Completion date | Oct. 1, 2021 |
| Required reporting date | Oct. 1, 2022, midnight |
| Actual reporting date | Sept. 29, 2022 |
| Date last checked at ClinicalTrials.gov | Oct. 31, 2025 |
| Days late | None |